Ex Parte WEICHSELBAUM et al - Page 4


                 Appeal No. 1999-1458                                                                                     
                 Application No. 07/943,812                                                                               
                 THE REJECTION UNDER 35 U.S.C. § 112, SECOND PARAGRAPH:                                                   
                         As set forth in Amgen Inc. v. Chugai Pharmaceutical Co., Ltd., 927 F.2d                          
                 1200, 1217, 18 USPQ2d 1016, 1030 (Fed. Cir. 1991):                                                       
                                The statute requires that “[t]he specification shall conclude                             
                         with one or more claims particularly pointing out and distinctly                                 
                         claiming the subject matter which the applicant regards as his                                   
                         invention.”  A decision as to whether a claim is invalid under this                              
                         provision requires a determination whether those skilled in the art                              
                         would understand what is claimed.  See Shatterproof Glass Corp.                                  
                         v. Libbey-Owens Ford Co., 758 F.2d 613, 624, 225 USPQ 634, 641                                   
                         (Fed. Cir. 1985) (Claims must “reasonably apprise those skilled in                               
                         the art” as to their scope and be “as precise as the subject matter                              
                         permits.”).                                                                                      
                         Furthermore, claim language must be analyzed “not in a vacuum, but                               
                 always in light of the teachings of the prior art and of the particular application                      
                 disclosure as it would be interpreted by one possessing the ordinary skill in the                        
                 pertinent art.”  In re Moore, 439 F.2d 1232, 1235, 169 USPQ 236, 238 (CCPA                               
                 1971).                                                                                                   
                         According to the examiner (Answer, page 4) “[c]laims 1, 54 and 55 are                            
                 indefinite in their recitation of nucleotide numbers because the frame of                                
                 reference (i.e. which base is “0” or “1”) is not clearly defined.”  In response,                         
                 appellants argue (Brief, page 5) that:                                                                   
                         [A]s a matter of scientific convenience, the base numbering of                                   
                         upstream regulatory regions typically relates to the start of                                    
                         transcription for the corresponding gene. Thus, even if there were                               
                         no information in the literature on the numbering for these particular                           
                         genes, and no guidance in the instant specification as to what                                   
                         regions are encompassed by the recitation of “-550 to –50,” the                                  
                         claims would, nonetheless, be clear.  Those of skill in the art would                            
                         understand the claims to include those residues that are 50 to 550                               
                         bases upstream of the translational start site, simply by convention.                            



                                                            4                                                             



Page:  Previous  1  2  3  4  5  6  7  8  9  10  11  12  13  14  Next 

Last modified: November 3, 2007